Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
July’s Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
|3||4||Johnson & Johnson*||1,416||699||176||15|
|12||10||Merck & co||269||146||14||4|
|41||42||Mitsubishi tanabe pharma||2||0||0||0|
July’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by HCPs on Twitter during July 2020 were Gilead, Pfizer, AstraZeneca, Johnson and Johnson (J&J), and GSK
Gilead maintained its position as the most mentioned pharmaceutical company for a 5th month due largely to its COVID-19 treatment candidate, remdesivir. Of all mentions of a Top 50 Pharma company by HCPs on Twitter, COVID-19 made up 43% of the conversation. Key drivers within this conversation included price discussions related to remdesivir as well as reactions to general trial results. At the beginning and middle of the month respectively, Pfizer and BioNTech as well as AstraZeneca and Oxford’s COVID-19 vaccine candidates received positive and promising results whilst at the end of the month, Roche’s tocilizumab was found to have no benefit for COVID-19 pneumonia.
I was glad to see @pfizer put up their phase 1 trial data today. Virus neutralizing antibody titers achieved after two doses are greater than convalescent antibody titers. Maybe the first objective good news we've seen out of Operation Warp Speed?https://t.co/uzp4bKkpAm
— Prof Peter Hotez MD PhD (@PeterHotez) July 1, 2020
Very good news from the Oxford vaccine trial. Glad to see both antibody and T cell responses.
How glad? Well sign me up for the vaccine!
— Vincent Rajkumar (@VincentRK) July 20, 2020
In the rest of the conversation, seperate from COVID-19, successful trial results, including for Bayer’s finerenone and Boehringer’s empagliflozin, reaped positive engagement from HCPs. One HCP in the US not only congratulated Bayer for their results but also two of the trialists involved in the study. Another US HCP shared Boehringer’s trial results adding his highlights from the report.
More great news for people with diabetic kidney disease: finerenone successful at preventing main renal and CV outcomes in the #FIDELIO trial. Congratulations to @AgarwalRajivMD and @BakrisGeorge as well as @Bayer ! https://t.co/f0J7pqKZQ4 pic.twitter.com/NPfZrkfHqg
— Vlado Perkovic (@VladoPerkovic) July 9, 2020
⚠️⚠️#EMPERORreduced trial via @Boehringer⤵️
📍 Empagliflozin meets primary endpoint in reducing risk of cardiovascular⚰️ or heart failure 🏨in Phase III trial in adults with and without diabetes@secardiologia @redGDPS @SEDiabetes @SociedadSeedo
— Alfonso Valle (@ValleAlfonso) July 30, 2020
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In July 2020, CREATION Pinpoint® identified 13,564 healthcare professional (HCP) authored tweets from 6,981 individual HCPs mentioning a top-50 pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 pharmaceutical company between July 1st and July 31th 2020.
- In some cases, a tweet may mention more than one company account (eg. @abbottnews and @abbottglobal) – this only counts as one Company Mention but two Account Mentions.
- The Number of Twitter Accounts Mentioned only include those accounts mentioned by HCPs.
- * Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In July, 534 of these posts mentioned Janssen.
- **Whilst included in the Top 50 Pharma list according to revenue from 2019, Shire has since been acquired by Takeda and no longer holds a Twitter account.